Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-31	US$0.000000	-	2

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 12:25:32 2026-06-01 EDT			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	-

12-28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 88.04K 81.94K 75.23K 142K 9.67M 144K 966K 379K 4.81M 380K 372K 16.14M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 9.85M 9.17M 8.42M 15.9M 1.08B 16.15M 108M 42.42M 539M 42.56M 41.63M 1.81B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	89.34%	Yield 2022 *	-	Yield 2023	-

12-28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
25-10-14	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-08-15	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
25-04-30	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
25-04-29	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
24-11-15	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
24-10-17	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
24-10-15	Top Midday Decliners	MT
24-10-14	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
24-09-27	Top Midday Decliners	MT
24-09-24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
24-09-24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

23-09-21	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
23-09-21	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
23-09-21	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
23-05-16	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
23-03-24	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Stock

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Valuation: Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news : Seelos Therapeutics, Inc.

Analysts' recommendations: Seelos Therapeutics, Inc.

Press Releases: Seelos Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

24-11-22	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
24-10-24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
24-10-24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
24-10-15	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
24-10-15	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Current year	0		0.01
1 year	0		0.01
3 years	0		6,374.41
5 years	0		10,713.61
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	2018-12-31
Michael Golembiewski DFI	Director of Finance/CFO	54	2021-08-31
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/29/24	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
1/12/24	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%
1/12/24	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	+9,900.00%	-.--%	-.--%	-100.00%	136
WUXI APPTEC CO., LTD.	+2.35%	+2.74%	+38.10%	+71.29%	56.54B
ARGENX SE	-0.21%	-7.38%	+27.52%	+61.15%	53.6B
BIONTECH SE	-2.44%	+1.40%	-15.61%	-15.45%	22.91B
INSMED INCORPORATED	-2.85%	-7.78%	-9.28%	+345.55%	21.37B
WUXI BIOLOGICS (CAYMAN) INC.	+2.49%	-0.92%	+23.57%	-13.14%	20.27B
GENMAB A/S	+0.79%	-1.06%	+33.99%	-31.95%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.58%	-5.88%	+19.40%	+527.50%	14.75B
PHARMAESSENTIA CORPORATION	+3.41%	-6.61%	+162.81%	+278.22%	13.53B
EXELIXIS, INC.	-5.25%	-4.23%	+42.32%	+170.15%	13.33B
Average	+989.89%	-3.41%	+32.28%	+129.33%	23.39B
Weighted average by Cap.	+0.23%	-2.96%	+30.79%	+116.84%

	2022	2023
Net sales	-	2.2 1.92 1.78 1.64 3.09 210.3 3.14 21.01 8.25 104.7 8.27 8.09 351.06
Net income	-73.53M -63.92M -59.5M -54.63M -103M -7.02B -105M -701M -275M -3.49B -276M -270M -11.72B	-37.88M -32.93M -30.65M -28.14M -53.14M -3.62B -53.97M -361M -142M -1.8B -142M -139M -6.04B
Net Debt	4.59M 3.99M 3.71M 3.41M 6.44M 438M 6.54M 43.77M 17.18M 218M 17.23M 16.86M 731M	11.23M 9.76M 9.09M 8.34M 15.76M 1.07B 16M 107M 42.04M 534M 42.18M 41.26M 1.79B